Articles related to TYPE 2 DIABETES

Hyperglycemia is associated with poor clinical outcomes in critically ill patients. Most medical societies recommend less stringent glucose control, in the range of 140 to 180 mg/dL, for critically ill patients. In this population, although glucose management is essential, hypoglycemia is associated with increased mortality. Enhancing the amount of time glucose levels are in the target range and minimizing glycemic variability have been associated with improved outcomes in critically ill patients.

Diabetes medications, such as metformin, have glucose-independent effects on the male reproductive system. However, until now, it was unknown if these effects lead to birth defects in offspring. This study concludes that metformin intake in men is associated with major birth defects, particularly genital birth defects in boys.

Thinking of starting the new year off with a diet? According to U.S. News and World Report, the Mediterranean diet is the best overall diet for adults. The diet was ranked first in the categories of best diets for healthy eating, easiest diets to follow, and best diets for diabetes, among other measurable categories.

More than half of adult Americans (60%) have at least one chronic condition that eventually lead to disability, mortality, and reduced quality of life. And chronic conditions account for 90% of America’s $3.8 trillion in annual healthcare costs. The CDC says these are the eight most expensive.

Publication: JAMA Internal MedicineDesign: Retrospective cohort study of more than 83,000 propensity-scored matched pairs over a 12-year period.Results: Diabetes progression was significantly greater among diabetes patients using statins vs. those not using statins.

Our understanding of lipid pathology is shifting from what might be called the “LDL hypothesis” to the “atherogenic lipoprotein hypothesis.” LDL is just a surrogate of the actual process of lipoprotein interaction with the arterial wall. This shift in understanding is driving a host of budding therapies with novel approaches to targeting key atherogenesis players like lipoprotein(a) and triglycerides.